With 0.57 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.02 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $15.762 whereas the lowest price it dropped to was $14.62. The 52-week range on NAMS shows that it touched its highest point at $27.29 and its lowest point at $14.06 during that stretch. It currently has a 1-year price target of $44.33. Beta for the stock currently stands at 0.18.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAMS was down-trending over the past week, with a drop of -4.36%, but this was down by -35.88% over a month. Three-month performance dropped to -39.40% while six-month performance fell -14.48%. The stock lost -20.84% in the past year, while it has lost -41.17% so far this year. A look at the trailing 12-month EPS for NAMS yields -2.60 with Next year EPS estimates of -1.84. For the next quarter, that number is -0.50. This implies an EPS growth rate of 29.95% for this year and -2.48% for next year.
Float and Shares Shorts:
At present, 108.06 million NAMS shares are outstanding with a float of 61.06 million shares on hand for trading. On 2025-03-31, short shares totaled 5.34 million, which was 486.00003000000004 higher than short shares on 1740700800. In addition to Dr. Michael Harvey Davidson FACC, Facp., M.D. as the firm’s CEO, President, Executive Board Member & Director, Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. serves as its Founder, Chief Scientific Officer, Member of Executive Board & Director.
Institutional Ownership:
Through their ownership of 0.99334997 of NAMS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, NAMS reported revenue of $12772000.0 and operating income of -$46434000.0. It generated -$92177000.0 net income for the quarter, which came to $35.40M over the last twelve months. The EBITDA in the recently reported quarter was -$58260000.0 and diluted EPS was $nan. EBITDA for the full year was $33.80M.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NAMS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NAMS analysts setting a high price target of 56.256256 and a low target of 38.917686, the average target price over the next 12 months is 47.204037. Based on these targets, NAMS could surge 272.07% to reach the target high and rise by 157.39% to reach the target low. Reaching the average price target will result in a growth of 212.2% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.73313 being high and -$2.04739 being low. For NAMS, this leads to a yearly average estimate of -$1.96168. Based on analyst estimates, the high estimate for the next quarter is -$0.37 and the low estimate is -$0.48. The average estimate for the next quarter is thus -$0.42.
